Mizuho on Axsome Therapeutics (AXSM): 'we recommend being opportunistic on any continued weakness'
Tweet Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $216.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments "AXSM ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
